Immune Reconstitution SLE Models

Autoimmune Nephropathy Models and Efficacy Services
IgA NephropathyC3 GlomerulonephritisLupus NephritisMembranous Nephropathy
Asthma Models and Efficacy Services
HDM induced asthma modelsOVA induced asthma models
Systemic Lupus Erythematosus (SLE) Models and Efficacy Services
Spontaneous SLE ModelsInduction SLE ModelsImmune Reconstitution SLE Models
Sjögren's Syndrome Models and Efficacy Services
Salivary Gland Protein Induced Sjögren's Syndrome Mouse ModelSTING Agonist Induced Sjögren’s Syndrome Mouse Model
Neuroimmune Diseases Models and Efficacy Services
Multiple Sclerosis (MS) ModelsMyasthenia Gravis (MG) Models
Autoimmune Dermatoses Models and Efficacy Services
Psoriasis ModelsAtopic DermatitisAlopecia Areata (AA)Vitiligo ModelsSclerodermaUrticariaPsoriatic Arthritis
Inflammatory Bowel Disease (IBD) Models and Efficacy Services
DSS Induced IBD ModelAdaptive T cell Transfer IBD ModelImmune Reconstitution IBD ModelAnti-CD40 Induced Colitis Models
Rheumatoid Arthritis (RA) Models and Efficacy Services
Collagen induced Arthritis ModelCollagen Antibody induced Arthritis ModelImmune Reconstitution Arthritis ModelmBSA induced DTHA Model
Immune Reconstitution Autoimmune Disease Models and Efficacy Services
SLEIBDArthritisMyasthenia GravisPassive Cutaneous AnaphylaxisPassive Systemic Anaphylaxis (PSA)

Patient-derived PBMC-NCG SLE model


1.jpeg

  

The levels of serum IgGs


D14 post reconstitution  


2.jpeg


Treating with Blincyto and tri-specific antibody showed inhibition of human anti-dsDNA IgG in SLE model, as well as human total IgG one week after administration,

 

D28 post reconstitution

 

3.jpeg

Blincyto and tri-specific antibody showed inhibition of human anti-dsDNA IgG in SLE model, as well as human IgG three weeks after administration. 

 

Immune cells population


4.png

Blincyto and tri-specific antibody showed depletion of B cells (CD 20+), memory B cells (CD27+) and plasma B cells three weeks after administration.

 

IgG deposition in Kidney  


5.png  

Blincyto and tri-specific antibody showed inhibition of human IgG deposition in SLE model three weeks after administration,

 

 

Induction of SLE model in HSC reconstitution mice


6.jpeg


Serum IgG levels


7.jpeg

HSC-NCG SLE model responded to anti-CD3-CD19 bispecific antibody, anti-CD3-BCMA bispecific antibody and Rituximab with lower of serum anti-DNA IgG levels detected post-treatment.


Immune cells population


D13 FACS of blood

 

8.png

 

D27 FACS of blood

 

9.png

HSC-NCG SLE model responded to anti-CD3-CD19 bispecific antibody, anti-CD3-BCMA bispecific antibody and Rituximab with lower levels of circulating CD3+ and Cd19+ cells detected post-treatment.

 

D27 FACS of spleen

 

10.png

HSC-NCG SLE model responded to anti-CD3-CD19 bispecific antibody, anti-CD3-BCMA bispecific antibody and Rituximab with lower levels of CD3+, Cd19+, T follicular helper cells (TFH), plasma B-cells, plasmablast cells and marginal zone B-cells (MZB) detected post-treatment.

TALK WITH OUR EXPERTS

GemPharmatech is committed to protecting and respecting your privacy, and we'll only use your personal information to administer your account and to provide the products and services you requested from us. From time to time, we would like to contact you about our products and services, as well as other content that may be of interest to you. If you consent to us contacting you for this purpose, please click below to say how you would like us to contact you:

In order to provide you with the content requested, we need to store and process your personal data. If you consent to us storing your personal data for this purpose, please click the checkbox below.

You can unsubscribe from these communications at any time. For more information on how to unsubscribe, our privacy practices, and how we are committed to protecting and respecting your privacy, please review our Privacy Policy.